Newborn affected by noxious substances transmitted via placenta or breast milk (P04)
Instructional Notations
Includes
This note appears immediately under a three character code title to further define, or give examples of, the content of the category.
- nonteratogenic effects of substances transmitted via placenta
Code First
Certain conditions have both an underlying etiology and multiple body system manifestations due to the underlying etiology. For such conditions, the ICD-10-CM has a coding convention that requires the underlying condition be sequenced first followed by the manifestation. Wherever such a combination exists, there is a "use additional code" note at the etiology code, and a "code first" note at the manifestation code. These instructional notes indicate the proper sequencing order of the codes, etiology followed by manifestation.
- any current condition in newborn, if applicable
Type 2 Excludes
A type 2 excludes note represents "Not included here". An excludes2 note indicates that the condition excluded is not part of the condition represented by the code, but a patient may have both conditions at the same time. When an Excludes2 note appears under a code, it is acceptable to use both the code and the excluded code together, when appropriate.
- congenital malformations Q00 Q99
- encounter for observation of newborn for suspected diseases and conditions ruled out Z05
- neonatal jaundice from excessive hemolysis due to drugs or toxins transmitted from mother P58.4
- newborn in contact with and suspected exposures hazardous to health not transmitted via placenta or breast milk Z77
Certain conditions originating in the perinatal period (P00–P96)
Newborn affected by maternal factors and by complications of pregnancy, labor, and delivery (P00-P04)
P04 Newborn affected by noxious substances transmitted via placenta or breast milk
- P04.0 Newborn affected by maternal anesthesia and analgesia in pregnancy, labor and delivery
P04.1 Newborn affected by other maternal medication
- P04.11 Newborn affected by maternal antineoplastic chemotherapy
- P04.12 Newborn affected by maternal cytotoxic drugs
- P04.13 Newborn affected by maternal use of anticonvulsants
- P04.14 Newborn affected by maternal use of opiates
- P04.15 Newborn affected by maternal use of antidepressants
- P04.16 Newborn affected by maternal use of amphetamines
- P04.17 Newborn affected by maternal use of sedative-hypnotics
- P04.18 Newborn affected by other maternal medication
- P04.19 Newborn affected by maternal use of unspecified medication
- P04.1A Newborn affected by maternal use of anxiolytics
- P04.2 Newborn affected by maternal use of tobacco
- P04.3 Newborn affected by maternal use of alcohol
P04.4 Newborn affected by maternal use of drugs of addiction
- P04.40 Newborn affected by maternal use of unspecified drugs of addiction
- P04.41 Newborn affected by maternal use of cocaine
- P04.42 Newborn affected by maternal use of hallucinogens
- P04.49 Newborn affected by maternal use of other drugs of addiction
- P04.5 Newborn affected by maternal use of nutritional chemical substances
- P04.6 Newborn affected by maternal exposure to environmental chemical substances
P04.8 Newborn affected by other maternal noxious substances
- P04.81 Newborn affected by maternal use of cannabis
- P04.89 Newborn affected by other maternal noxious substances
- P04.9 Newborn affected by maternal noxious substance, unspecified
Newborn affected by noxious substances transmitted via placenta or breast milk (P04)